A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data.

Published on Jun 9, 2020in International Journal of Clinical Oncology2.879
· DOI :10.1007/S10147-020-01692-Z
Nobuyuki Hinata17
Estimated H-index: 17
(Kobe University),
Junji Yonese24
Estimated H-index: 24
+ 17 AuthorsHirotsugu Uemura36
Estimated H-index: 36
(Kindai University)
Sources
Abstract
BACKGROUND In a phase III clinical trial, CheckMate 025, treatment of metastatic renal cell carcinoma (mRCC) with nivolumab demonstrated superior efficacy over everolimus. However, as the clinical trial excluded patients with specific complications and poor performance status (PS), the effectiveness and safety of nivolumab in clinical practice, in which patients with various clinical complications are treated, is unclear. This study explored real-world nivolumab treatment in Japanese mRCC patients. METHODS This is an interim analysis of a multicenter, non-interventional, medical record review study (minimum follow-up: 9 months). All eligible Japanese mRCC patients who first received nivolumab between February and October 2017 were included; data cut-off was April 2019. We analyzed nivolumab treatment patterns, efficacy (including overall survival, progression-free survival, objective response rate, and duration of response) and safety (including immune-related adverse events). RESULTS Of 208 evaluable patients, 31.7% received nivolumab as fourth- or later line of treatment. At data cut-off, 26.9% of patients were continuing nivolumab treatment. The major reason for discontinuation was disease progression (n = 100, 65.8%). Median overall survival was not reached; the 12-month survival rate was 75.6%. Median progression-free survival was 7.1 months, the objective response rate was 22.6%, and median duration of response was 13.3 months. Patients who were excluded or limited in number in CheckMate 025, such as those with non-clear cell RCC or poor PS, also received benefits from nivolumab treatment. Immune-related adverse events occurred in 27.4% of patients (grade ≥ 3, 10.1%). CONCLUSION Nivolumab was effective and well-tolerated in real-world Japanese mRCC patients. TRIAL REGISTRATION UMIN000033312.
📖 Papers frequently viewed together
1 Citations
6 Citations
8 Authors (J. Hack, ..., Matthew Wheater)
References18
Newest
#1Yoshihiko Tomita (Niigata University)H-Index: 27
#2Satoshi FukasawaH-Index: 13
Last. Hirotsugu Uemura (Kindai University)H-Index: 36
view all 12 authors...
BACKGROUND: Nivolumab treatment resulted in superior efficacy and safety versus everolimus treatment in the 2-year follow-up of the CheckMate 025 Phase III study, with consistent results in the global population and the Japanese population. Here, we report the 3-year follow-up in both groups. METHODS: Patients were randomized 1:1 to nivolumab 3 mg/kg intravenously every 2 weeks or everolimus 10 mg orally once daily until progression/intolerable toxicity. The primary endpoint was overall survival...
23 CitationsSource
#3Jeffrey Graham (U of C: University of Calgary)H-Index: 9
Objectives In the present study, we explored the real-world efficacy of the immuno-oncology checkpoint inhibitor nivolumab and the tyrosine kinase inhibitor cabozantinib in the second-line setting. Methods Using the International Metastatic Renal Cell Carcinoma Database Consortium (imdc) dataset, a retrospective analysis of patients with metastatic renal cell carcinoma (mrcc) treated with nivolumab or cabozantinib in the second line after prior therapy targeted to the vascular endothelial growth...
14 CitationsSource
The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval. Pts with previously treated advanced or mRCC were eligible to receive nivolumab 3 mg/kg every 2 weeks. Pts included in the analysis had received ≥1 dose of nivolumab and were monitored for drug-related adverse events (drAEs) using CTCAE v.4.0. Immune-related (ir) AEs were defined as AEs dis...
55 CitationsSource
Last. Scott S. Tykodi (Fred Hutchinson Cancer Research Center)H-Index: 25
view all 16 authors...
562Background: Initial safety results from the phase 3b/4 CheckMate 374 study showed that flat-dose nivolumab (NIVO) at 240 mg every 2 wk (Q2W) had a consistent safety profile across patients (pts)...
9 CitationsSource
#1Ken-ichi Harada (Kobe University)H-Index: 17
#2Masahiro Nozawa (Kindai University)H-Index: 13
Last. Hirotsugu Uemura (Kindai University)H-Index: 36
view all 16 authors...
OBJECTIVES: To clarify treatment patterns and outcomes for patients with unresectable or metastatic renal cell carcinoma in the molecular target therapy era in Japan. METHODS: A multicenter, retrospective medical chart review study was carried out. Patients diagnosed with unresectable or metastatic renal cell carcinoma between January 2012 and August 2015 were enrolled. Data extracted from medical records included treatment duration, grade ≥3 adverse events, reason for discontinuation for each t...
15 CitationsSource
Purpose Immune-checkpoint inhibitors (ICIs) represent the standard of care for platinum-pretreated advanced non-small cell lung cancer patients. Patients treated with ICIs may experience immune-related adverse events (irAEs), that might reflect antitumor responses. Here we evaluated nivolumab efficacy according to the development of irAEs.
123 CitationsSource
#1Aly-Khan A. Lalani (McMaster University)H-Index: 12
#2Bradley Alexander McGregor (Harvard University)H-Index: 17
Last. Axel Bex (NKI-AVL: Netherlands Cancer Institute)H-Index: 54
view all 8 authors...
Abstract Context Systemic therapy for metastatic clear cell renal cell carcinoma (mccRCC) has greatly evolved over the last 15 yr. More recently, combination strategies involving contemporary immunotherapy have emerged as key opportunities to further shift the treatment landscape. Objective To review the evidence regarding the efficacy and safety of standard therapeutic options in mccRCC as well as combination immunotherapy options on the horizon. Evidence acquisition PubMed/Medline, Embase, Web...
85 CitationsSource
#1Yuichiro OheH-Index: 71
#2Akihiko Gemma (Nippon Medical School)H-Index: 57
Last. Y. Nakanishi (Kyushu University)H-Index: 5
view all 8 authors...
3 CitationsSource
#1Steven YipH-Index: 8
#2Connor WellsH-Index: 5
Last. Daniel Y.C. HengH-Index: 29
view all 19 authors...
BACKGROUND: To the authors' knowledge, outcomes and prognostic tools have yet to be clearly defined in patients with metastatic renal cell carcinoma (mRCC) who are treated with immuno-oncology (IO) checkpoint inhibitors (programmed death-ligand 1 [PD-L1] inhibitors). In the current study, the authors aimed to establish IO efficacy benchmarks in patients with mRCC and update patient outcomes in each International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic class. METHODS...
31 CitationsSource
#1Kosuke Ueda (Kurume University)H-Index: 7
#2Shigetaka Suekane (Kurume University)H-Index: 21
Last. Tsukasa Igawa (Kurume University)H-Index: 17
view all 10 authors...
AIM: To investigate prognostic factors for patients with advanced renal cell carcinoma (RCC) treated with axitinib as second-line therapy. PATIENTS AND METHODS: This study included 35 patients with RCC who received axitinib as second-line therapy after the failure of first-line tyrosine kinases inhibitor from November 2012 to March 2017. RESULTS: In univariate analyses, the following factors were associated with poor prognosis: bone and extrapulmonary metastasis for progression-free survival; an...
6 CitationsSource
Cited By5
Newest
#1Irene Resch (Medical University of Vienna)H-Index: 5
#2Andreas Bruchbacher (Medical University of Vienna)H-Index: 3
Last. Manuela Schmidinger (Medical University of Vienna)H-Index: 28
view all 7 authors...
Background null Immune checkpoint inhibitors (ICIs) have led to a paradigm change in the management of metastatic renal cell carcinoma (mRCC). Prospective trials have focused on ICI treatment in the first or second line. The aim of this analysis is to evaluate the benefit of ICI across different treatment lines. null null null Patients and methods null This is a single-center retrospective study that included mRCC patients who received ICIs in various treatment lines. Objective response rates (O...
Source
Abstract null null The introduction of checkpoint inhibitors (ICIs) in renal cell carcinoma (RCC) treatment landscape, resulted in improvements in overall survival (OS) in metastatic patients. Brain metastases (BMs) are a specific metastatic site of interest representing a predictive factor of poor prognosis. Patients with BMs were usually excluded from prospective clinical trials in the past. Despite recent evidence suggest the efficacy and safety of ICIs, the BMs treatment remains a challenge;...
1 CitationsSource
#1Makoto Sumitomo (Fujita Health University)H-Index: 4
#2Kiyoshi Takahara (Fujita Health University)H-Index: 14
Last. Ryoichi Shiroki (Fujita Health University)H-Index: 12
view all 15 authors...
Indoleamine 2,3-dioxygenase 1 (IDO1) is a key enzyme associated with immunomodulation through its regulation of the tryptophan-kynurenine (Kyn) pathway in advanced cancers, including metastatic renal cell carcinoma (mRCC). However, the failure of IDO1 inhibitors when used in combination with immune checkpoint inhibitors (ICIs), as observed in clinical trials, raises a number of questions. This study aimed to investigate the association of tryptophan 2,3-dioxygenase (TDO) and IDO1 with cancer dev...
3 CitationsSource
#1Taigo Kato (Osaka University)H-Index: 10
#2Akira NagaharaH-Index: 19
Last. Motohide Uemura (Osaka University)H-Index: 26
view all 18 authors...
BACKGROUND Recent studies have shown that immune-related adverse events (irAEs) caused by immune checkpoint inhibitors (ICIs) were correlated with favorable clinical outcome in patients with melanoma. However, in metastatic renal cell carcinoma (mRCC) patients, there have been few reports about the correlation between irAEs and clinical efficacy of anti-programmed cell death protein-1 (PD-1) therapy. METHODS We retrospectively investigated 160 mRCC patients who started nivolumab monotherapy betw...
1 CitationsSource
#1Taigo Kato (Osaka University)H-Index: 10
#2Kazuma Kiyotani (JFCR: Japanese Foundation for Cancer Research)H-Index: 28
Last. Motohide Uemura (Osaka University)H-Index: 26
view all 15 authors...
Immune checkpoint inhibitors (ICIs) offer significant clinical benefits to a subset of cancer patients via the induction of a systemic T cell-mediated anti-cancer immune response. Thus, the dynamic...
1 CitationsSource